Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

MDM2 SNP309 and risk of endometrial cancer.

Knappskog S, Lønning PE.

Pol J Pathol. 2013 Apr;64(1):69-70. No abstract available.

PMID:
23625604
[PubMed - indexed for MEDLINE]
2.

Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.

Zając A, Stachowiak G, Pertyński T, Romanowicz H, Wilczyński J, Smolarz B.

Pol J Pathol. 2012 Dec;63(4):278-83.

PMID:
23359199
[PubMed - indexed for MEDLINE]
3.

MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.

Li Y, Zhao H, Sun L, Huang L, Yang Q, Kong B.

Hum Cell. 2011 Jun;24(2):57-64. doi: 10.1007/s13577-011-0013-4. Epub 2011 Mar 4. Review.

PMID:
21547352
[PubMed - indexed for MEDLINE]
4.

Letter to the editor reply.

Zając A, Stachowiak G, Pertyński T, Romanowicz H, Wilczyński J, Smolarz B.

Pol J Pathol. 2013 Apr;64(1):70. No abstract available.

PMID:
23625605
[PubMed - indexed for MEDLINE]
5.

Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.

Walsh CS, Miller CW, Karlan BY, Koeffler HP.

Gynecol Oncol. 2007 Mar;104(3):660-4. Epub 2006 Nov 21.

PMID:
17123590
[PubMed - indexed for MEDLINE]
6.

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.

Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, Wake N.

Oncol Rep. 2013 Jul;30(1):25-34. doi: 10.3892/or.2013.2433. Epub 2013 Apr 29.

PMID:
23624782
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.

Peng Q, Mo C, Qin A, Lao X, Chen Z, Sui J, Wu J, Zhai L, Yang S, Qin X, Li S.

J Exp Clin Cancer Res. 2013 Nov 3;32:85. doi: 10.1186/1756-9966-32-85.

PMID:
24423195
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis.

Bai J, Dai J, Yu H, Shen H, Chen F.

J Toxicol Environ Health A. 2009;72(11-12):677-82. doi: 10.1080/15287390902840930.

PMID:
19492228
[PubMed - indexed for MEDLINE]
9.

MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis.

Ma Y, Bian J, Cao H.

PLoS One. 2013;8(2):e56918. doi: 10.1371/journal.pone.0056918. Epub 2013 Feb 25.

PMID:
23451111
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.

Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY.

Brain Res. 2008 Mar 10;1198:16-20. doi: 10.1016/j.brainres.2008.01.027. Epub 2008 Jan 18.

PMID:
18262501
[PubMed - indexed for MEDLINE]
11.

Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.

Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, Okamoto Y, Torii K, Noda S.

Hum Cell. 2009 Nov;22(4):101-6. doi: 10.1111/j.1749-0774.2009.00075.x.

PMID:
19874399
[PubMed - indexed for MEDLINE]
12.

Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.

Leu JD, Wang CY, Tsai HY, Lin IF, Chen RC, Lee YJ.

Oncol Rep. 2011 Jun;25(6):1755-63. doi: 10.3892/or.2011.1254. Epub 2011 Apr 8.

PMID:
21479369
[PubMed - indexed for MEDLINE]
13.

MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.

Wan Y, Wu W, Yin Z, Guan P, Zhou B.

BMC Cancer. 2011 May 29;11:208. doi: 10.1186/1471-2407-11-208.

PMID:
21619694
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.

Zhao E, Cui D, Yuan L, Lu W.

Mol Biol Rep. 2012 Apr;39(4):3471-7. doi: 10.1007/s11033-011-1119-1. Epub 2011 Jul 3.

PMID:
21725850
[PubMed - indexed for MEDLINE]
15.

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.

Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC; MoMaTEC study group, Romundstad P, Hveem K, Vatten L, Salvesen HB, Lønning PE.

Eur J Cancer. 2012 Sep;48(13):1988-96. doi: 10.1016/j.ejca.2011.10.024. Epub 2011 Nov 24.

PMID:
22119201
[PubMed - indexed for MEDLINE]
16.

MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.

Ryan BM, Calhoun KM, Pine SR, Bowman ED, Robles AI, Ambs S, Harris CC.

Int J Cancer. 2012 Dec 1;131(11):2710-6. doi: 10.1002/ijc.27573. Epub 2012 Apr 27.

PMID:
22487911
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer.

Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U, Scott RJ.

Gynecol Oncol. 2009 Apr;113(1):109-14. doi: 10.1016/j.ygyno.2008.12.036. Epub 2009 Feb 3.

PMID:
19193430
[PubMed - indexed for MEDLINE]
18.

Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?

Tuna G, Küçükhüseyin O, Arıkan S, Kaytan Sağlam E, Güler E, Cacına C, Oztop O, Turan S, Korkmaz G, Yaylım I.

DNA Cell Biol. 2013 Jul;32(7):400-8. doi: 10.1089/dna.2012.1933. Epub 2013 Jun 18.

PMID:
23777425
[PubMed - indexed for MEDLINE]
19.

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.

Kaderi MA, Mansouri M, Zainuddin N, Cahill N, Gunnarsson R, Jansson M, Kimby E, Aleskog A, Lundin J, Glimelius B, Melbye M, Juliusson G, Jurlander J, Rosenquist R.

Leuk Res. 2010 Mar;34(3):335-9. doi: 10.1016/j.leukres.2009.06.006. Epub 2009 Jul 1.

PMID:
19573916
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk